Advertisement
Advertisement
PBLS
Parabilis Medicines, Inc. Common Stock
26.73
USDSponsored
+0.21
+0.81%
Oct 28, 14:04 UTC -4
Open
Parabilis Medicines, Inc. Common Stock (PBLS) Earnings
PBLS Earnings Reports
Positive Surprise Ratio
PBLS beat 0 of 1 last estimates.
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Parabilis Medicines, Inc. Common Stock earnings per share and revenue
On Aug 13, 2026, PBLS reported earnings of -2.12 USD per share (EPS) for Q2 26, missing the estimate of 0.08 USD, resulting in a -2698.04% surprise. Revenue reached 148.00 thousand, compared to an expected 25.50 million, with a -99.42% difference. The market reacted with a -4.65% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Repligen Corp
Report Date
Oct 27, 2026 For Q3 26
Estimate
$0.46
Actual
$0.53
Surprise
+12.79%
argenx SE - ADR
Report Date
Oct 22, 2026 For Q3 26
Estimate
$8.19
Actual
$7.80
Surprise
-4.84%
Biogen Inc. Common Stock
Report Date
Oct 28, 2026 For Q3 26
Estimate
$2.01
Actual
$2.62
Surprise
+30.13%
QIAGEN N.V.
Report Date
Oct 21, 2026 For Q3 26
Estimate
$0.63
Actual
$0.65
Surprise
+2.43%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
Oct 27, 2026 For Q3 26
Estimate
$0.02
Actual
$0.30
Surprise
+1,165.82%
Nautilus Biotechnolgy, Inc. Common Stock
Report Date
Oct 27, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.12
Surprise
+15.97%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Oct 26, 2026 For Q3 26
Estimate
-$0.39
Actual
-$0.35
Surprise
+11.79%
Tiziana Life Sciences Ltd. Common Shares
Report Date
Oct 16, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.10
Surprise
-22.55%
FAQ
What were Parabilis Medicines, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Parabilis Medicines, Inc. Common Stock reported EPS of -$2.12, missing estimates by -2698.04%, and revenue of $148.00K, -99.42% below expectations.
How did the market react to Parabilis Medicines, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -4.65%, changed from $37.41 before the earnings release to $35.67 the day after.
When is Parabilis Medicines, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Parabilis Medicines, Inc. Common Stock's next earnings report?
Based on --
analysts, Parabilis Medicines, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.